Alimera Sciences (ALIM) 10-Q 11 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 07, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'ALIMERA SCIENCES INC	'
Entity Central Index Key	'0001267602	'
Document Type	'10-Q	'
Document Period End Date	30-Jun-14	'
Amendment Flag	'false	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	40,424,241

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
CURRENT ASSETS:	'	'
Cash and cash equivalents	$41,986	$12,628
Accounts receivable, net	1,020	500
Prepaid expenses and other current assets	2,560	3,474
Inventory, net	1,372	1,786
Deferred financing costs	597	250
Total current assets	47,535	18,638
PROPERTY AND EQUIPMENT — at cost less accumulated depreciation	1,123	982
TOTAL ASSETS	48,658	19,620
CURRENT LIABILITIES:	'	'
Accounts payable	1,851	1,735
Accrued expenses	1,118	934
Outsourced services payable	1,236	603
Note payable	0	1,667
Capital lease obligations	10	10
Total current liabilities	4,215	4,949
NON-CURRENT LIABILITIES:	'	'
Derivative warrant liability	21,457	16,381
Note payable, net of discount — less current portion	9,313	3,194
Other non-current liabilities	14	21
COMMITMENTS AND CONTINGENCIES	'	'
STOCKHOLDERS’ EQUITY (DEFICIT):	'	'
Common stock, $.01 par value — 100,000,000 shares authorized, 40,340,712 shares issued and outstanding at June 30, 2014 and 31,610,991 shares issued and outstanding at December 31, 2013	403	316
Additional paid-in capital	282,384	240,135
Accumulated deficit	-296,989	-277,345
Accumulated other comprehensive loss	-345	-488
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)	13,659	-4,925
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	48,658	19,620
Preferred Stock	'	'
STOCKHOLDERS’ EQUITY (DEFICIT):	'	'
Preferred stock	'	'
Series A convertible preferred stock	'	'
STOCKHOLDERS’ EQUITY (DEFICIT):	'	'
Preferred stock	27,238	32,045
Common Stock	'	'
STOCKHOLDERS’ EQUITY (DEFICIT):	'	'
Common stock warrants	$968	$412

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized (shares)	100,000,000	100,000,000
Common stock, shares issued (shares)	40,340,712	31,610,991
Common stock, shares outstanding (shares)	40,340,712	31,610,991
Preferred Stock	'	'
Preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, shares authorized (shares)	10,000,000	10,000,000
Series A convertible preferred stock	'	'
Preferred stock, shares authorized (shares)	1,300,000	1,300,000
Preferred stock, shares issued (shares)	850,000	1,000,000
Preferred stock, shares outstanding (shares)	850,000	1,000,000
Preferred stock, liquidation preference	$34,000,000	$40,000,000

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Statement [Abstract]	'	'	'	'
NET REVENUE	$2,190,000	$179,000	$4,274,000	$179,000
COST OF GOODS SOLD	-376,000	-11,000	-940,000	-11,000
GROSS MARGIN	1,814,000	168,000	3,334,000	168,000
RESEARCH AND DEVELOPMENT EXPENSES	1,809,000	2,180,000	4,435,000	4,203,000
GENERAL AND ADMINISTRATIVE EXPENSES	2,827,000	2,429,000	5,754,000	5,099,000
SALES AND MARKETING EXPENSES	3,136,000	4,898,000	6,547,000	8,461,000
OPERATING EXPENSES	7,772,000	9,507,000	16,736,000	17,763,000
INTEREST EXPENSE, NET AND OTHER	-325,000	-129,000	-454,000	-263,000
UNREALIZED FOREIGN CURRENCY LOSS, NET	-146,000	0	-202,000	0
CHANGE IN FAIR VALUE OF DERIVATIVE WARRANT LIABILITY	8,054,000	-6,742,000	-5,076,000	-12,336,000
LOSS ON EARLY EXTINGUISHMENT OF DEBT	-440,000	-153,000	-440,000	-153,000
NET INCOME (LOSS) BEFORE TAXES	1,185,000	-16,363,000	-19,574,000	-30,347,000
PROVISION FOR TAXES	-69,000	0	-69,000	0
NET INCOME (LOSS)	1,116,000	-16,363,000	-19,643,000	-30,347,000
ACCRETION OF PREFERRED STOCK BENEFICIAL CONVERSION FEATURE	0	-4,950,000	0	-4,950,000
NET INCOME (LOSS) APPLICABLE TO COMMON STOCKHOLDERS	$1,116,000	($21,313,000)	($19,643,000)	($35,297,000)
NET INCOME (LOSS) PER SHARE APPLICABLE TO COMMON STOCKHOLDERS — Basic (in dollars per share)	$0.03	($0.67)	($0.52)	($1.12)
WEIGHTED AVERAGE SHARES OUTSTANDING — Basic (shares)	40,275,638	31,574,858	38,076,968	31,560,294
NET LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDERS — Diluted (in dollars per share)	($0.16)	($0.67)	($0.52)	($1.12)
WEIGHTED AVERAGE SHARES OUTSTANDING — Diluted (shares)	42,548,254	31,574,858	38,076,968	31,560,294

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
NET INCOME (LOSS)	$1,116	($16,363)	($19,643)	($30,347)
OTHER COMPREHENSIVE LOSS	'	'	'	'
Foreign currency translation adjustments	139	37	143	45
TOTAL OTHER COMPREHENSIVE LOSS	139	37	143	45
COMPREHENSIVE INCOME (LOSS)	$1,255	($16,326)	($19,500)	($30,302)

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net loss	($19,643)	($30,347)
Loss from early extinguishment of debt	440	153
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	69	59
Unrealized foreign currency transaction loss	202	0
Amortization of deferred financing costs and debt discount	94	82
Stock-based compensation expense	1,849	990
Change in fair value of derivative warrant liability	5,076	12,336
Changes in assets and liabilities:	'	'
Accounts receivable	-526	-129
Prepaid expenses and other current assets	894	-1,177
Inventory	400	-1,094
Accounts payable	122	1,132
Accrued expenses and other current liabilities	827	-902
Other long-term liabilities	-2	-201
Net cash used in operating activities	-10,198	-19,098
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'
Purchases of property and equipment	-210	-381
Net cash used in investing activities	-210	-381
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Proceeds from exercise of stock options	334	59
Proceeds from sale of common stock	37,543	33
Payment of issuance cost of common stock	-2,389	0
Payment of principal on notes payable	-4,861	-3,067
Payment of debt extinguishment costs	-246	0
Proceeds from issuance of notes payable	10,000	5,000
Payment of debt costs	-645	-223
Payment of capital lease obligations	-5	-7
Net cash provided by financing activities	39,731	1,795
EFFECT OF EXCHANGE RATES ON CASH AND CASH EQUIVALENTS	35	45
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	29,358	-17,639
CASH AND CASH EQUIVALENTS — Beginning of period	12,628	49,564
CASH AND CASH EQUIVALENTS — End of period	41,986	31,925
SUPPLEMENTAL DISCLOSURES:	'	'
Cash paid for interest	224	183
Supplemental schedule of non-cash investing and financing activities:	'	'
Property and equipment under capital leases	$0	$33

Nature_of_Operations

Nature of Operations	6 Months Ended
	Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
NATURE OF OPERATIONS	'
	NATURE OF OPERATIONS
	Alimera Sciences, Inc., and its wholly-owned subsidiaries (the Company), is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company was formed on June 4, 2003 under the laws of the State of Delaware.
	The Company is presently focused on diseases affecting the back of the eye, or retina, because the Company’s management believes these diseases are not well treated with current therapies and represent a significant market opportunity. The Company’s only commercial product is ILUVIEN®, which has received marketing authorization in the United Kingdom, Austria, Portugal, France, Germany, Spain, Italy, Norway and Denmark, and has been recommended for marketing authorization in eight additional European Union (EU) countries, for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. ILUVIEN is the first product approved for chronic DME in the EU. As part of the approval process in these countries, the Company has committed to conduct a five-year, post-authorization, open label registry study of ILUVIEN in 800 patients treated per the labeled indication. ILUVIEN has not been approved by the U.S. Food and Drug Administration (FDA), but a New Drug Application (NDA) is currently under review with the FDA.
	The Company launched ILUVIEN in the United Kingdom and Germany in April and May of 2013, respectively, and currently plans to launch ILUVIEN in France and Portugal in late 2014. The Company was able to launch in Germany without price restrictions, but continues to work with the statutory health insurance funds in Germany to streamline reimbursement for ILUVIEN.
	In October 2013, the United Kingdom’s National Institute for Health and Care Excellence (NICE) issued a positive Final Appraisal Determination recommending ILUVIEN funding, taking into consideration a simple patient access scheme (PAS) for the treatment of pseudophakic eyes (eyes with an artificial lens) in chronic DME patients considered insufficiently responsive to available therapies. The final technology appraisal guidance was published in November 2013. NICE requires clinical commissioning groups, National Health Service (NHS) England and Wales, and local public health authorities to comply with the recommendations in the final guidance within three months of its date of publication. The Company began receiving orders for ILUVIEN from several NHS facilities in January 2014, indicating early implementation of the NICE guidance in certain NHS facilities. Further, in February 2014, the Scottish Medicines Consortium, after completing its assessment and review of a similar simple PAS, announced that is has accepted ILUVIEN for restricted use within the NHS Scotland.
	In July 2013, the Transparency Commission (Commission de la Transparence or CT) of the French National Health Authority (Haute Autorite de Sante) issued a favorable opinion for the reimbursement and hospital listing of ILUVIEN for the treatment of chronic DME considered insufficiently responsive to available therapies. In the opinion, ILUVIEN was deemed as providing a "moderate medical benefit" as defined by the Service Medical Rendu. The Company has not yet agreed on a price with the French authorities. When the Company and the French authorities agree on a price for ILUVIEN, patients will be reimbursed for 100% of the cost of ILUVIEN under the Affection de Longue Duree, a specific program for severe chronic diseases such as diabetes. When comparing the clinical benefit of ILUVIEN to existing therapies , the CT rated the product at "level IV" (Amelioration du Service Medical Rendu or ASMR) which will be used in considering the price and any reimbursement conditions for ILUVIEN in France.
	In September 2013, the Company submitted an application to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom, as the Reference Member State, for ten additional EU country approvals through the Mutual Recognition Procedure (MRP). In June 2014, the Company received a positive outcome from the Repeat-Use Procedure for ILUVIEN for the treatment of chronic DME in Ireland, the Netherlands, Belgium, Luxembourg, Sweden, Denmark, Finland, Norway, Poland and the Czech Republic. The regulatory process in these countries has entered the national phase in which each country grants marketing authorization. In July 2014, the Company received the first marketing authorizations resulting from the MRP in Norway and Denmark.
	The Company submitted a NDA in June 2010 for ILUVIEN in the U.S. with the FDA. The Company resubmitted its NDA with revisions in May 2011 and April 2013 to address matters raised in the FDA's Complete Response Letters (CRLs) relating to the NDA. In October 2013, the Company received a third CRL from the FDA stating that the NDA could not be approved in its current form. In the third CRL, the FDA identified clinical and statistical deficiencies and indicated that the benefits of ILUVIEN did not outweigh its risks. Further, the FDA also indicated that results from a new clinical trial would need to be submitted, together with at least 12 months of follow-up data for all enrolled patients, to support certain indications previously discussed with the FDA. The FDA suggested that a meeting with the Dermatologic and Ophthalmic Drugs Advisory Committee may be of assistance in addressing the deficiencies identified above and providing advice whether a patient population can be identified in which the benefits of the drug product might outweigh the risks. In the third CRL, the FDA also referenced deficiencies in the methods and controls used for the drug product at the facility where ILUVIEN is manufactured.
	The Company was notified of a January 2014 meeting of the Advisory Committee, shortly after the issuance of the third CRL. In a subsequent communication with the FDA, the Company believes it clarified that the purpose of the Advisory Committee meeting was to consider the benefits and risks of ILUVIEN based on existing data available from its two completed Phase 3 pivotal clinical trials. A meeting with the FDA in preparation for the Advisory Committee resulted in labeling discussions for ILUVIEN, and the Company and the FDA agreed that the Advisory Committee was no longer necessary.
	In March 2014, the Company resubmitted its NDA for ILUVIEN in response to the third CRL. In the resubmission, the Company responded to questions raised in the third CRL, addressed deficiencies noted in the methods and controls used for the drug product at the facility where ILUVIEN is manufactured and provided a safety update, which included commercial experience with ILUVIEN in Europe. In April 2014, the Company was notified by the FDA that the resubmission of its NDA for ILUVIEN had been acknowledged as received by the FDA as a complete class 2 response to the third CRL, and that a Prescription Drug User Fee Act (PDUFA) goal date of September 26, 2014 had been established. The Company does not plan to conduct any new clinical trials in connection with the FDA's review of this submission.
	In the third CRL, the FDA also referenced deficiencies in the methods and controls used for the drug product at the third party facility where ILUVIEN is manufactured. In July 2014, the third party facility received a notification from the Los Angeles District of the Department of Health and Human Services (LA District) after their pre-approval and good manufacturing practice inspection of the facility in connection with the Company's NDA. In that notification, the LA District recommended approval of the NDA by the FDA. This is only a recommendation which the FDA is not obligated to follow. Only the FDA can issue an official approval of the NDA.
	In July 2014, the Company reached agreement with INFARMED, the marketing authorization body of the Portuguese Ministry of Health, for the pricing and reimbursement of ILUVIEN for the public sector in Portugal. The Company currently plans to make ILUVIEN commercially available in Portugal in late 2014.

Basis_of_Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
BASIS OF PRESENTATION	'
	BASIS OF PRESENTATION
	The Company has prepared the accompanying unaudited interim condensed consolidated financial statements and notes thereto (interim financial statements) in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and the instructions to Form 10-Q and Article 10-01 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements reflect all adjustments, which include normal recurring adjustments, necessary to present fairly the Company’s interim financial information.
	The accompanying unaudited interim condensed consolidated financial statements and related notes should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2013 and related notes included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on March 7, 2014. The financial results for any interim period are not necessarily indicative of the expected financial results for the full year.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	The accounting policies followed for quarterly financial reporting are the same as those disclosed in the Notes to Financial Statements included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended December 31, 2013.
	Recent Accounting Pronouncements
	From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.
	In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606).” ASU 2014-09 provides a single, comprehensive revenue recognition model for all contracts with customers. The revenue guidance contains principles that an entity will apply to determine the measurement of revenue and timing of when it is recognized. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016 for public entities, with no early adoption permitted. The Company is still evaluating the potential impact of adopting this guidance on the financial statements.
	In June 2014, the FASB issued ASU 2014-12, “Compensation Stock - Compensation (Topic 718).” ASU 2014-12 applies to all reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target that affects vesting could be achieved after the requisite service period. It requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition and follows existing accounting guidance for the treatment of performance conditions. The standard will be effective for annual periods and interim periods within those annual periods beginning after December 15, 2015, with early adoption permitted. The Company is still evaluating the potential impact of adopting this guidance on the financial statements.

Factors_Affecting_Operations

Factors Affecting Operations	6 Months Ended
	Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
FACTORS AFFECTING OPERATIONS	'
	FACTORS AFFECTING OPERATIONS
	To date the Company has incurred negative cash flow from operations, and has accumulated a deficit of $296,989,000 from the Company’s inception through June 30, 2014. As of June 30, 2014, the Company had approximately $41,986,000 in cash and cash equivalents.
	The Company believes that it has sufficient funds available to fund its operations beyond the projected commercialization of ILUVIEN in Germany, the United Kingdom, Portugal and France. The Company does not expect the generation of positive cash flow from operations until late 2015, at the earliest, if at all. If ILUVIEN is not approved in additional jurisdictions or does not generate sufficient revenue, the Company may adjust its commercial plans so that it can continue to operate with its existing cash resources or seek to raise additional financing.
	The accompanying interim condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company's negative cash flow from operations and accumulated deficit raise substantial doubt about its ability to continue as a going concern. The interim condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Inventory

Inventory	6 Months Ended
	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
INVENTORY	'
	INVENTORY
	Inventory consisted of the following:
		June 30,			December 31, 2013
		2014
		(In thousands)
	Component parts (1)	$	152		$	266
	Work-in-process (2)	607			587
	Finished goods	1,267			1,343
	Total inventory	2,026			2,196
	Inventory reserve	(654		)	(410		)
	Inventory — net	$	1,372		$	1,786
	(1) Component parts inventory consisted of manufactured components of the ILUVIEN applicator.
	(2) Work-in-process consisted of completed units of ILUVIEN that are undergoing, but have not completed, quality assurance testing as required by regulatory authorities.

Accrued_Expenses

Accrued Expenses	6 Months Ended
	Jun. 30, 2014
Payables and Accruals [Abstract]	'
ACCRUED EXPENSES	'
	ACCRUED EXPENSES
	Accrued expenses consisted of the following:
		June 30,		December 31, 2013
		2014
		(In thousands)
	Accrued clinical investigator expenses	$	327	$	562
	Accrued other compensation expenses	725		106
	Other accrued expenses	66		266
	Total accrued expenses	$	1,118	$	934

License_Agreements

License Agreements	6 Months Ended
	Jun. 30, 2014
Disclosure P Sivida Agreement Additional Information [Abstract]	'
LICENSE AGREEMENTS	'
	LICENSE AGREEMENTS
	The Company entered into an agreement with pSivida US, Inc. (pSivida) for the use of fluocinolone acetonide (FAc) in pSivida’s proprietary delivery device in February 2005, and a subsequent amendment in 2008. pSivida is a global drug delivery company committed to the biomedical sector and the development of drug delivery products. The agreement with pSivida provides the Company with a worldwide exclusive license to develop and sell ILUVIEN.
	The Company’s license rights to pSivida’s proprietary delivery device could revert to pSivida if the Company were to (i) fail twice to cure its breach of an obligation to make certain payments to pSivida following receipt of written notice thereof; (ii) fail to cure other breaches of material terms of its agreement with pSivida within 30 days after notice of such breaches or such longer period (up to 90 days) as may be reasonably necessary if the breach cannot be cured within such 30-day period; (iii) file for protection under the bankruptcy laws, make an assignment for the benefit of creditors, appoint or suffer appointment of a receiver or trustee over its property, file a petition under any bankruptcy or insolvency act or have any such petition filed against it and such proceeding remains undismissed or unstayed for a period of more than 60 days; or (iv) notify pSivida in writing of its decision to abandon its license with respect to a certain product using pSivida’s proprietary delivery device.
	The Company must share 20% of the net profits of ILUVIEN and 33% of any lump sum milestone payments received from a sub-licensee of ILUVIEN, as defined by the agreement, with pSivida. In connection with this arrangement the Company is entitled to recover 20% of commercialization costs of ILUVIEN, as defined in the agreement, incurred prior to product profitability out of pSivida’s share of net profits. As of June 30, 2014 and December 31, 2013, the Company was owed $12,971,000 and $12,219,000, respectively, in commercialization costs. Due to the uncertainty of future net profits, the Company has fully reserved these amounts in the accompanying interim condensed consolidated financial statements. The Company will owe pSivida an additional milestone payment of $25,000,000 if ILUVIEN is approved by the FDA (the pSivida Milestone Payment).
	In November 2007, the Company entered into a license agreement with Dainippon Sumitomo Pharma Co., Ltd. (Dainippon) whereby Dainippon granted the Company a non-exclusive, worldwide, royalty free license to patent rights under specific patents and patent applications. The Company paid $200,000 to Dainippon shortly after the execution of this license agreement and will be required to make an additional payment in the amount of $200,000 to Dainippon within 30 days following the first regulatory approval of a licensed product in the U.S. by the FDA.

Loan_Agreements

Loan Agreements	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
LOAN AGREEMENTS	'
	LOAN AGREEMENTS
	2013 Loan Agreement
	In May 2013, Alimera Sciences Limited (Limited) entered into a loan and security agreement (2013 Loan Agreement) with Silicon Valley Bank (SVB) to provide Limited with additional working capital for general corporate purposes. Under the 2013 Loan Agreement, SVB made a term loan (2013 Term Loan) in the principal amount of $5,000,000 to Limited and agreed to provide up to an additional $15,000,000 to Limited under a working capital line of credit (2013 Line of Credit). In connection with the 2013 Loan Agreement, a previous term loan was repaid in full and terminated. In accordance with ASC 470-50-40-17, the Company recognized a loss on early extinguishment of debt of $153,000 during the three and six months ended June 30, 2013, associated with the remaining unamortized deferred financing costs, unamortized discount associated with the warrants issued to the lenders, a final interest payment, a prepayment penalty and a lender fee and warrants associated with the 2013 Loan Agreement. No advances were made at closing under the 2013 Line of Credit and no amounts were outstanding as of December 31, 2013. In April 2014, the 2013 Term Loan was repaid and the 2013 Line of Credit was terminated in connection with the 2014 Loan Agreement described below.
	The 2013 Term Loan provided for interest only payments for six months followed by 36 monthly payments of interest, plus principal. Limited made its first amortization payment on the 2013 Term Loan in December 2013. Interest on outstanding borrowings under the 2013 Term Loan were payable at the rate of 7.50%. Borrowings under the 2013 Line of Credit would have been advanced at 80% of eligible accounts receivable as defined in the 2013 Loan Agreement. Interest was payable on the balance of eligible accounts financed at the rate of 2.75% above SVB's most recently announced “prime rate.” Limited was also required to pay SVB on a monthly basis an unused line fee equal to 0.25% per annum of the average unused portion of the 2013 Line of Credit during the preceding month. The maturity dates were June 30, 2015 with respect to the 2013 Line of Credit and October 31, 2016 with respect to the 2013 Term Loan.
	In connection with entering into the 2013 Loan Agreement, Limited paid SVB a facility fee of $25,000. Additionally, the Company re-priced warrants to purchase an aggregate of up to 31,818 shares of the Company’s common stock previously issued to SVB in connection with an earlier term loan. Upon re-pricing, each of the warrants was exercisable immediately at a per-share exercise price of $2.86 and had a remaining term of 7.4 years. The Company estimated the incremental fair value received by SVB using the Black-Scholes option pricing model to be $46,000. In accordance with ASC 470-50-40-17, the Company expensed the facility fee and incremental value of the warrants associated with the 2013 Term Loan as part of the loss on early extinguishment of the earlier term loan. During the three and six months ended June 30, 2013 the Company incurred interest expense of $11,000 and $44,000, respectively, in connection with the earlier term loan.
	In connection with the 2013 Line of Credit, Limited paid a commitment fee of $100,000. In accordance with ASC 470-50-40-17, the Company capitalized the commitment fee and $49,000 of deferred financing costs remaining on an earlier line of credit as deferred financing costs, which were being amortized over the remaining term of the 2013 Line of Credit.
	Upon repayment of the 2013 Term Loan in April 2014, Limited paid SVB an outstanding loan balance prepayment penalty of $133,000, and an early termination fee of $113,000 in connection with the termination of the 2013 Line of Credit in April 2014.
	2014 Loan Agreement
	In April 2014, Limited entered into a loan and security agreement (2014 Term Loan) with Hercules Technology Growth Capital, Inc. (Hercules). Under the 2014 Term Loan, Hercules made an advance in the initial principal amount of $10,000,000 to Limited at closing to provide Limited with additional working capital for general corporate purposes and to repay the 2013 Term Loan. Hercules also agreed to provide up to an additional $25,000,000 to Limited upon approval of ILUVIEN by the FDA on or prior to October 31, 2014 to fund the pSivida Milestone Payment. The 2014 Term Loan provides for interest only payments for 18 months. The interest only period may be extended by an additional 18 months if the Company realizes certain revenue thresholds and no event of default has occurred under the 2014 Loan Agreement. Interest on the 2014 Term Loan accrues at a floating per annum rate equal to the greater of (i) 10.90%, or (ii) the sum of (A) 7.65%, plus (B) the prime rate. Following the interest only period the term loan will be due and payable to Hercules in equal monthly payments of principal and interest through May 1, 2018.
	Limited paid to Hercules a facility charge of $262,500 and incurred legal and other fees of approximately $383,000 in connection with the 2014 Term Loan. If Limited repays the 2014 Term Loan prior to maturity, it will pay Hercules a prepayment penalty of 1.25% of the total principal amount repaid.
	Limited and the Company, on a consolidated basis with its other subsidiaries, also agreed to customary affirmative and negative covenants and events of default in connection with these arrangements. The occurrence of an event of default could result in the acceleration of Limited’s obligations under the Loan Agreement and an increase to the applicable interest rate, and would permit Hercules to exercise remedies with respect to the collateral under the Loan Agreement.
	Limited’s obligations to Hercules are secured by a first priority security interest in substantially all of Limited’s assets, excluding intellectual property. Hercules does, however, maintain a negative pledge on Limited’s intellectual property requiring Hercules' consent prior to the sale of such intellectual property. The Company and certain of the Company’s other subsidiaries are guarantors of the obligations of Limited to Hercules under the Loan Agreement pursuant to separate guaranty agreements between Hercules and each of Limited and such subsidiaries (Guaranties). Pursuant to the Guaranties, the Company and these subsidiaries granted Hercules a first priority security interest in substantially all of their respective assets excluding intellectual property.
	In connection with Limited entering into the 2014 Loan Agreement, the Company entered into a warrant agreement with Hercules to purchase up to 285,016 shares of the Company’s common stock at an exercise price of $6.14 per share. Sixty percent of the warrants were exercisable at closing and the remaining 40% will become exercisable if the remaining $25,000,000 is advanced to the Company prior to October 31, 2014.
	The weighted average interest rates of the Company's notes payable approximate the rate at which the Company could obtain alternative financing; therefore, the carrying amount of the notes approximated their fair value at June 30, 2014 and December 31, 2013.

Earnings_Loss_Per_Share_EPS

Earnings (Loss) Per Share (EPS)	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
LOSS PER SHARE (EPS)	'
	EARNINGS (LOSS) PER SHARE (EPS)
	Basic EPS is calculated in accordance with ASC 260, Earnings per Share, by dividing net income or loss attributable to common stockholders by the weighted average common stock outstanding. Diluted EPS is calculated in accordance with ASC 260 by adjusting weighted average common shares outstanding for the dilutive effect of common stock options, warrants and convertible preferred stock. In periods where a net loss is recorded, no effect is given to potentially dilutive securities, since the effect would be anti-dilutive. Common stock equivalent securities that would potentially dilute basic EPS in the future, but were not included in the computation of diluted EPS because to do so would have been anti-dilutive, were as follows:
		Three Months Ended June 30,						Six Months Ended June 30,
		2014			2013			2014		2013
	Series A convertible preferred stock	12,781,954			15,037,593			12,781,954		15,037,593
	Series A convertible preferred stock warrants	—			4,511,279			4,511,279		4,511,279
	Common stock warrants	248,964			152,567			248,964		152,567
	Stock options	7,599,768			5,895,838			7,599,768		5,895,838
	Total	20,630,686			25,597,277			25,141,965		25,597,277
	The following table sets forth the computation of basic and diluted EPS:
		Three Months Ended June 30,							Six Months Ended June 30,
		2014				2013			2014			2013
	Numerator:
	Numerator for basic EPS - net income (loss) applicable to common stockholders	$	1,116,000			$	(21,313,000	)	$	(19,643,000	)	$	(35,297,000	)
	Effect of dilutive securities:
	Change in fair value of derivative warrant liability (Note 10)	(8,054,000		)		—			—			—
	Numerator for diluted EPS - net loss applicable to common stockholders after assumed conversions	$	(6,938,000	)		$	(21,313,000	)	$	(19,643,000	)	$	(35,297,000	)
	Denominator:
	Denominator for basic EPS - weighted average shares outstanding	40,275,638				31,574,858			38,076,968			31,560,294
	Effect of dilutive securities:
	Preferred stock warrants (Note 10)	2,272,616				—			—			—
	Denominator for diluted EPS - adjusted weighted average shares and assumed conversions outstanding	42,548,254				31,574,858			38,076,968			31,560,294
	Basic EPS	0.03				(0.67		)	(0.52		)	(1.12		)
	Diluted EPS	(0.16		)		(0.67		)	(0.52		)	(1.12		)

Preferred_Stock

Preferred Stock	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
PREFERRED STOCK	'
	PREFERRED STOCK
	On October 2, 2012, the Company closed its preferred stock financing in which it sold units consisting of 1,000,000 shares of Series A Convertible Preferred Stock and warrants to purchase 300,000 shares of Series A Convertible Preferred Stock for gross proceeds of $40,000,000, prior to the payment of approximately $560,000 of related issuance costs. The powers, preferences and rights of the Series A Convertible Preferred Stock are set forth in the certificate of designation filed by the Company with the Secretary of State of the State of Delaware on October 1, 2012. Each share of Series A Convertible Preferred Stock, including any shares of Series A Convertible Preferred Stock issued upon exercise of the warrants, is convertible into shares of the Company’s common stock at any time at the option of the holder at the rate equal to $40.00 divided by the then current conversion price (Conversion Price). The initial Conversion Price of $2.91 of the Series A Convertible Preferred Stock was subject to adjustment to $3.16 or $2.66 based on the occurrence or non-occurrence of certain events relating to guidance from NICE regarding ILUVIEN, in addition to certain customary price based anti-dilution adjustments. Each share of Series A Convertible Preferred Stock shall automatically be converted into shares of common stock at the then-effective Conversion Price upon the occurrence of the later to occur of both (i) the Company receives and publicly announces the approval by the FDA of the Company’s NDA for ILUVIEN and (ii) the date on which the Company consummates an equity financing transaction pursuant to which the Company sells to one or more third party investors either (a) shares of common stock or (b) other equity securities that are convertible into shares of common stock and that have rights, preference or privileges, senior to or on a parity with, the Series A Convertible Preferred Stock, in each case having an as-converted per share of common stock price of not less than $10.00 and that results in total gross proceeds to the Company of at least $30,000,000. The rights and preferences of Series A Convertible Preferred Stock also place limitations on the Company's ability to declare or pay any dividend or distribution on any shares of capital stock.
	On June 30, 2013, the Conversion Price was automatically adjusted to $2.66. As a result of the adjustment to the Conversion Price, the value of the common stock underlying the Series A Convertible Preferred Stock at issuance exceeded the amount of the net proceeds allocated to the Series A Convertible Preferred Stock at issuance. Therefore, the Company recorded the contingent beneficial conversion feature of $4,950,000 as an increase in additional paid in capital. Because the Series A Convertible Preferred Stock was immediately convertible into common stock at the option of the holder on June 30, 2013, the Company immediately accreted the full value of the beneficial conversion feature to the carrying value of the Series A Convertible Preferred Stock on that date.
	Each unit sold in the preferred stock financing included a warrant to purchase 0.30 shares of Series A Convertible Preferred Stock at an exercise price equal to $44.00 per share. At the election of the holder of a warrant, the warrant may be exercised for the number of shares of common stock then issuable upon conversion of the Series A Convertible Preferred Stock that would otherwise be issued upon such exercise at the then-effective Conversion Price.
	These warrants are considered derivative instruments because the agreements provide for settlement in Series A Convertible Preferred Stock shares or common stock shares at the option of the holder, an adjustment to the warrant exercise price for common shares at some point in the future, and contain anti-dilution provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants are subject to change in the event of certain issuances of stock at prices below the then-effective exercise price of the warrants. Therefore the warrants were recorded as a liability at issuance. At June 30, 2014 and December 31, 2013, the fair market value of the warrants was estimated to be $21,457,000 and $16,381,000, respectively. During the three months ended June 30, 2014 and 2013, the Company recorded a gain of $8,054,000 and a loss of $6,742,000, respectively, as a result of the change in fair value of the warrants. During the six months ended June 30, 2014 and 2013, the Company recorded losses of $5,076,000 and $12,336,000, respectively, as a result of the change in fair value of the warrants.
	In April 2014, 2,255,639 shares of common stock were issued pursuant to a conversion of 150,000 shares of Series A Preferred Stock held by an investor.

Common_Stock

Common Stock	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
COMMON STOCK	'
	COMMON STOCK
	In January 2014, the Company entered into a securities purchase agreement with certain investors pursuant to which the Company sold an aggregate of 6,250,000 shares of its common stock at a purchase price of $6.00 per share. Gross proceeds from the offering were $37,500,000 prior to the payment of approximately $2,389,000 of related issuance costs. Proceeds from the private placement are expected to be used for general corporate and working capital purposes.
	During the three and six months ended June 30, 2014 and 2013, 23,487 and 15,174 shares of the Company’s common stock were acquired through its employee stock purchase plan resulting in proceeds of $43,000 and $33,000, respectively.

Stock_Incentive_Plans

Stock Incentive Plans	6 Months Ended
	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
STOCK INCENTIVE PLANS	'
	STOCK INCENTIVE PLANS
	Stock Option Plans
	During the three months ended June 30, 2014 and 2013, the Company recorded compensation expense related to stock options of approximately $904,000 and $448,000, respectively. During the six months ended June 30, 2014 and 2013, the Company recorded compensation expense related to stock options of approximately $1,829,000 and $976,000, respectively. As of June 30, 2014, the total unrecognized compensation cost related to non-vested stock options granted was $5,668,000 and is expected to be recognized over a weighted average period of 2.63 years. The following table presents a summary of stock option activity for the three and six months ended June 30, 2014 and 2013:
		Three Months Ended June 30,												Six Months Ended June 30,
		2014							2013					2014					2013
		Options				Weighted			Options			Weighted		Options			Weighted		Options			Weighted
						Average						Average					Average					Average
						Exercise						Exercise					Exercise					Exercise
						Price						Price					Price					Price
	Options outstanding at beginning of period	7,408,977				$	2.76		5,849,838			$	2.63	7,566,438			$	2.74	5,493,079			$	2.67
	Grants	315,000				5.66			172,500			5.26		315,000			5.66		560,000			3.09
	Forfeitures	(99,167		)		2.54			(106,500		)	1.66		(99,167		)	2.54		(122,412		)	2.06
	Exercises	(25,042		)		1.88			(20,000		)	1.33		(182,503		)	1.83		(34,829		)	1.7
	Options outstanding at period end	7,599,768				2.88			5,895,838			2.73		7,599,768			2.88		5,895,838			2.73
	Options exercisable at period end	3,903,668				3.15			2,836,201			3.05		3,903,668			3.15		2,836,201			3.05
	Weighted average per share fair value of options granted during the period	$	4.5						$	4.01				$	4.5				$	2.38
	The following table provides additional information related to outstanding stock options, exercisable stock options, and stock options expected to vest as of June 30, 2014:
		Shares			Weighted			Weighted		Aggregate
					Average			Average		Intrinsic
					Exercise			Contractual		Value
					Price			Term
										(In thousands)
	Outstanding	7,599,768			$	2.88		7.35 years		$	25,657
	Exercisable	3,903,668			3.15			5.79 years		12,963
	Expected to vest	2,966,181			2.63			8.93 years		10,108
	The following table provides additional information related to outstanding stock options, exercisable stock options, and stock options expected to vest as of December 31, 2013:
		Shares			Weighted			Weighted		Aggregate
					Average			Average		Intrinsic
					Exercise			Contractual		Value
					Price			Term
										(In thousands)
	Outstanding	7,566,438			$	2.74		7.63 years		$	17,759
	Exercisable	3,304,981			3.09			5.45 years		7,589
	Expected to vest	3,469,118			2.48			9.25 years		8,314
	Employee Stock Purchase Plan
	During the three months ended June 30, 2014 and 2013, the Company recorded compensation expense related to its employee stock purchase plan of approximately $12,000 and $7,000, respectively. During the six months ended June 30, 2014 and 2013, the Company recorded compensation expense related to its employee stock purchase plan of approximately $20,000 and $13,000, respectively.

Income_Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
INCOME TAXES	'
	INCOME TAXES
	In accordance with ASC 740, Income Taxes, the Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities at the enacted tax rates in effect for the year in which the differences are expected to reverse. The Company records a valuation allowance against its net deferred tax asset to reduce the net carrying value to an amount that is more likely than not to be realized.
	At the end of each interim period, the Company makes its best estimate of the effective tax rate expected to be applicable for the full fiscal year. This estimate reflects, among other items, the Company’s best estimate of operating results and foreign currency exchange rates. The Company’s quarterly income tax rate may differ from its estimated annual effective tax rate because accounting standards require the Company to exclude the actual results of certain entities expected to generate a pretax loss when applying the estimated annual effective tax rate to the Company’s consolidated pretax results in interim periods. In estimating the annual effective tax rate, the Company does not include the estimated impact of unusual and/or infrequent items, including the reversal of valuation allowances, which may cause significant variations in the customary relationship between income tax expense (benefit) and pretax income (loss) in quarterly periods. The income tax expense (benefit) for such unusual and/or infrequent items is recorded in the quarterly period such items are incurred.
	The Company’s income tax expense and resulting effective tax rate are based upon the respective estimated annual effective tax rates applicable for the respective periods adjusted for the effects of items required to be treated as discrete to the period, including changes in tax laws, changes in estimated exposures for uncertain tax positions and other items. The Company’s effective tax rate for the three months ended June 30, 2014 properly excluded tax benefits associated with year-to-date pre-tax losses generated in the U.S. and the Netherlands. Income tax positions are considered for uncertainty in accordance with ASC 740-10. The Company believes that its income tax filing positions and deductions are more likely than not to be sustained on audit and the Company does not anticipate any adjustments that will result in a material change in its financial position; therefore, no ASC 740-10 liabilities and no related penalties and interest have been recorded. The Company does not anticipate any material changes to its uncertain tax positions within the next 12 months. Tax years since 2003 remain subject to examination in Georgia, Tennessee, and at the federal level. The time period is longer than the standard statutory 3-year period due to net operating losses (NOLs) from 2003 being available for utilization. The statute of limitations on these years will close when the NOLs expire or when the statute closes on the years in which the NOLs are utilized.
	Significant management judgment is involved in determining the provision for income taxes, deferred tax assets and liabilities, and any valuation allowance recorded against net deferred tax assets. Due to uncertainties with respect to the realization of deferred tax assets due to the history of operating losses, a valuation allowance has been established against the entire net deferred tax asset balance. The valuation allowance is based on management’s estimates of taxable income in the jurisdictions in which the Company operates and the period over which deferred tax assets will be recoverable. In the event that actual results differ from these estimates or the Company adjusts these estimates in future periods, a change in the valuation allowance may be needed, which could materially impact its financial position and results of operations.
	At December 31, 2013, the Company had federal NOL carryforwards of approximately $82,380,000 and state NOL carryforwards of approximately $65,840,000 available to reduce future income. The Company's federal NOL carry-forwards remain fully reserved as of June 30, 2014. If not utilized, the federal NOL carryforwards will expire at various dates between 2028 and 2032 and the state NOL carryforwards will expire at various dates between 2020 and 2032.
	The Company's NOL carryforwards may be subject to annual limitations under Internal Revenue Code (IRC) Section 382 (or comparable provisions of state law) in the event that certain changes in ownership of the Company were to occur. The Company periodically evaluates its NOL carryforwards and whether certain changes in ownership, including its IPO, have occurred that would limit its ability to utilize a portion of the Company's NOL carryforwards. If it is determined that significant ownership changes have occurred since the Company generated its NOL carryforwards, the Company may be subject to annual limitations on the use of these NOL carryforwards under IRC Section 382 (or comparable provisions of state law).
	The Company's foreign subsidiaries commenced business during 2013. One of these subsidiaries has incurred losses to date, and the NOL carryforwards of this foreign entity are fully reserved as of June 30, 2014. The Company has not recorded a deferred tax asset for the excess of tax over book basis in the stock of its foreign subsidiaries. The Company intends to indefinitely reinvest in its foreign subsidiaries all undistributed earnings of and original investments in such subsidiaries. As a result, the Company does not expect to record deferred tax liabilities in the future related to excesses of book over tax basis in the stock of its foreign subsidiaries in accordance with ASC 740-30-25.

Fair_Value

Fair Value	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
FAIR VALUE	'
	FAIR VALUE
	The Company applies ASC 820, Fair Value Measurements, in determining the fair value of certain assets and liabilities. Under this standard, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.
	In determining fair value, the Company uses various valuation approaches. The hierarchy of those valuation approaches is broken down into three levels based on the reliability of inputs as follows:
	Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. An active market for the asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. The valuation under this approach does not entail a significant degree of judgment.
	Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include: quoted prices for similar assets or liabilities in active markets, inputs other than quoted prices that are observable for the asset or liability, (e.g., interest rates and yield curves observable at commonly quoted intervals or current market) and contractual prices for the underlying financial instrument, as well as other relevant economic measures.
	Level 3 inputs are unobservable inputs for the asset or liability. Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.
	There have been no changes in the methodologies used at June 30, 2014 and December 31, 2013.
	The following fair value table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis:
		30-Jun-14
		Level 1		Level 2		Level 3		Total
		(In thousands)
	Assets:
	Cash equivalents (1)	$	29,194	$	—	$	—	$	29,194
	Assets measured at fair value	$	29,194	$	—	$	—	$	29,194
	Liabilities:
	Derivative warrant liability (2)	$	—	$	21,457	$	—	$	21,457
	Liabilities measured at fair value	$	—	$	21,457	$	—	$	21,457
		31-Dec-13
		Level 1		Level 2		Level 3		Total
		(In thousands)
	Assets:
	Cash equivalents (1)	$	6,944	$	—	$	—	$	6,944
	Assets measured at fair value	$	6,944	$	—	$	—	$	6,944
	Liabilities:
	Derivative warrant liability (2)	$	—	$	16,381	$	—	$	16,381
	Liabilities measured at fair value	$	—	$	16,381	$	—	$	16,381
	-1	The carrying amounts approximate fair value due to the short-term maturities of the cash equivalents.
	-2	The Company uses the Black-Scholes option pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments. Assumptions used are generally consistent with those disclosed for stock based compensation (see Note 12).

Inventory_Tables

Inventory (Tables)	6 Months Ended
	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory	'
	Inventory consisted of the following:
		June 30,			December 31, 2013
		2014
		(In thousands)
	Component parts (1)	$	152		$	266
	Work-in-process (2)	607			587
	Finished goods	1,267			1,343
	Total inventory	2,026			2,196
	Inventory reserve	(654		)	(410		)
	Inventory — net	$	1,372		$	1,786
	(1) Component parts inventory consisted of manufactured components of the ILUVIEN applicator.
	(2) Work-in-process consisted of completed units of ILUVIEN that are undergoing, but have not completed, quality assurance testing as required by regulatory authorities.

Accrued_Expenses_Tables

Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2014
Payables and Accruals [Abstract]	'
Summary of Accrued Expenses	'
	Accrued expenses consisted of the following:
		June 30,		December 31, 2013
		2014
		(In thousands)
	Accrued clinical investigator expenses	$	327	$	562
	Accrued other compensation expenses	725		106
	Other accrued expenses	66		266
	Total accrued expenses	$	1,118	$	934

Earnings_Loss_Per_Share_EPS_Ta

Earnings (Loss) Per Share (EPS) (Tables)	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Schedule of antidilutive securities excluded from computation of earnings per share	'
	Common stock equivalent securities that would potentially dilute basic EPS in the future, but were not included in the computation of diluted EPS because to do so would have been anti-dilutive, were as follows:
		Three Months Ended June 30,						Six Months Ended June 30,
		2014			2013			2014		2013
	Series A convertible preferred stock	12,781,954			15,037,593			12,781,954		15,037,593
	Series A convertible preferred stock warrants	—			4,511,279			4,511,279		4,511,279
	Common stock warrants	248,964			152,567			248,964		152,567
	Stock options	7,599,768			5,895,838			7,599,768		5,895,838
	Total	20,630,686			25,597,277			25,141,965		25,597,277
Schedule of Earnings Per Share, Basic and Diluted	'
	The following table sets forth the computation of basic and diluted EPS:
		Three Months Ended June 30,							Six Months Ended June 30,
		2014				2013			2014			2013
	Numerator:
	Numerator for basic EPS - net income (loss) applicable to common stockholders	$	1,116,000			$	(21,313,000	)	$	(19,643,000	)	$	(35,297,000	)
	Effect of dilutive securities:
	Change in fair value of derivative warrant liability (Note 10)	(8,054,000		)		—			—			—
	Numerator for diluted EPS - net loss applicable to common stockholders after assumed conversions	$	(6,938,000	)		$	(21,313,000	)	$	(19,643,000	)	$	(35,297,000	)
	Denominator:
	Denominator for basic EPS - weighted average shares outstanding	40,275,638				31,574,858			38,076,968			31,560,294
	Effect of dilutive securities:
	Preferred stock warrants (Note 10)	2,272,616				—			—			—
	Denominator for diluted EPS - adjusted weighted average shares and assumed conversions outstanding	42,548,254				31,574,858			38,076,968			31,560,294
	Basic EPS	0.03				(0.67		)	(0.52		)	(1.12		)
	Diluted EPS	(0.16		)		(0.67		)	(0.52		)	(1.12		)

Stock_Incentive_Plans_Tables

Stock Incentive Plans (Tables)	6 Months Ended
	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Summary of stock option transactions	'
	The following table presents a summary of stock option activity for the three and six months ended June 30, 2014 and 2013:
		Three Months Ended June 30,												Six Months Ended June 30,
		2014							2013					2014					2013
		Options				Weighted			Options			Weighted		Options			Weighted		Options			Weighted
						Average						Average					Average					Average
						Exercise						Exercise					Exercise					Exercise
						Price						Price					Price					Price
	Options outstanding at beginning of period	7,408,977				$	2.76		5,849,838			$	2.63	7,566,438			$	2.74	5,493,079			$	2.67
	Grants	315,000				5.66			172,500			5.26		315,000			5.66		560,000			3.09
	Forfeitures	(99,167		)		2.54			(106,500		)	1.66		(99,167		)	2.54		(122,412		)	2.06
	Exercises	(25,042		)		1.88			(20,000		)	1.33		(182,503		)	1.83		(34,829		)	1.7
	Options outstanding at period end	7,599,768				2.88			5,895,838			2.73		7,599,768			2.88		5,895,838			2.73
	Options exercisable at period end	3,903,668				3.15			2,836,201			3.05		3,903,668			3.15		2,836,201			3.05
	Weighted average per share fair value of options granted during the period	$	4.5						$	4.01				$	4.5				$	2.38
Summary of additional stock option transactions	'
	The following table provides additional information related to outstanding stock options, exercisable stock options, and stock options expected to vest as of June 30, 2014:
		Shares			Weighted			Weighted		Aggregate
					Average			Average		Intrinsic
					Exercise			Contractual		Value
					Price			Term
										(In thousands)
	Outstanding	7,599,768			$	2.88		7.35 years		$	25,657
	Exercisable	3,903,668			3.15			5.79 years		12,963
	Expected to vest	2,966,181			2.63			8.93 years		10,108
	The following table provides additional information related to outstanding stock options, exercisable stock options, and stock options expected to vest as of December 31, 2013:
		Shares			Weighted			Weighted		Aggregate
					Average			Average		Intrinsic
					Exercise			Contractual		Value
					Price			Term
										(In thousands)
	Outstanding	7,566,438			$	2.74		7.63 years		$	17,759
	Exercisable	3,304,981			3.09			5.45 years		7,589
	Expected to vest	3,469,118			2.48			9.25 years		8,314

Fair_Value_Tables

Fair Value (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Assets Measured at Fair Value on Recurring Basis	'
	The following fair value table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis:
		30-Jun-14
		Level 1		Level 2		Level 3		Total
		(In thousands)
	Assets:
	Cash equivalents (1)	$	29,194	$	—	$	—	$	29,194
	Assets measured at fair value	$	29,194	$	—	$	—	$	29,194
	Liabilities:
	Derivative warrant liability (2)	$	—	$	21,457	$	—	$	21,457
	Liabilities measured at fair value	$	—	$	21,457	$	—	$	21,457
		31-Dec-13
		Level 1		Level 2		Level 3		Total
		(In thousands)
	Assets:
	Cash equivalents (1)	$	6,944	$	—	$	—	$	6,944
	Assets measured at fair value	$	6,944	$	—	$	—	$	6,944
	Liabilities:
	Derivative warrant liability (2)	$	—	$	16,381	$	—	$	16,381
	Liabilities measured at fair value	$	—	$	16,381	$	—	$	16,381
	-1	The carrying amounts approximate fair value due to the short-term maturities of the cash equivalents.
	-2	The Company uses the Black-Scholes option pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments. Assumptions used are generally consistent with those disclosed for stock based compensation (see Note 12).

Nature_of_Operations_Detail

Nature of Operations (Detail) (ILUVIEN)	1 Months Ended	6 Months Ended	1 Months Ended	6 Months Ended
	Sep. 30, 2013	Jun. 30, 2014	Oct. 31, 2013	Jun. 30, 2014
	country	Patient	Maximum	French National Health Insurance
		clinical_trial
Nature Of Operations [Line Items]	'	'	'	'
Post-authorization open study period	'	'5 years	'	'
Planned drug study, number of patients	'	800	'	'
Insurance reimbursement rate	'	'	'	100.00%
Number of European countries where drug approval is sought	10	'	'	'
Patient follow-up data required to be submitted in conjunction with clinical trial results for drug approval	'	'	'12 months	'
Number of clinical trials completed	'	2	'	'

Factors_Affecting_Operations_D

Factors Affecting Operations (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'	'	'	'
Accumulated deficit	($296,989)	($277,345)	'	'
Cash and cash equivalents	$41,986	$12,628	$31,925	$49,564

Inventory_Components_of_Invent

Inventory - Components of Inventory (Detail) (USD $)	Jun. 30, 2014		Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory net realizable value	'		'
Component parts	$152	[1]	$266	[1]
Work-in-process	607	[2]	587	[2]
Finished goods	1,267		1,343
Total inventory	2,026		2,196
Inventory reserve	-654		-410
Inventory — net	$1,372		$1,786
[1]	Component parts inventory consisted of manufactured components of the ILUVIEN applicator.
[2]	Work-in-process consisted of completed units of ILUVIEN that are undergoing, but have not completed, quality assurance testing as required by regulatory authorities.

Accrued_Expenses_Summary_of_Ac

Accrued Expenses - Summary of Accrued Expenses (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Summary of accrued expenses	'	'
Accrued clinical investigator expenses	$327	$562
Accrued other compensation expenses	725	106
Other accrued expenses	66	266
Total accrued expenses	$1,118	$934

License_Agreements_Detail

License Agreements (Detail) (USD $)	6 Months Ended		1 Months Ended	6 Months Ended
	Jun. 30, 2014	Dec. 31, 2013	Nov. 30, 2007	Jun. 30, 2014
			Dainippon Sumitomo Pharma Co Ltd	pSivida
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'
Minimum days to require to revert license in case of breaches of contract	'	'	'	'30 days
Maximum days to require to revert license in case of breaches of contract	'	'	'	'90 days
Period of bankruptcy petition proceedings remains undismissed	'	'	'	'60 days
Share of net profits	20.00%	'	'	'
Share of any lump sum milestone payments received from a sub-licensee of ILUVIEN	33.00%	'	'	'
Recovery of commercialization costs	20.00%	'	'	'
Commercialization costs owned	$12,971,000	$12,219,000	'	'
Additional milestone payment after the first product approved by the FDA	'	'	'	25,000,000
Payments for license agreement	'	'	200,000	'
Additional payment for license agreement that the company will be required to make	'	'	$200,000	'
Period during which additional payment for license agreement is to be made	'	'	'30 days	'

Loan_Agreements_Additional_Inf

Loan Agreements - Additional Information (Detail) (USD $)

3 Months Ended

6 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

31-May-13

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2013

31-May-13

Apr. 30, 2014

Apr. 30, 2014

31-May-13

31-May-13

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Alimera Sciences, Inc.(Company)

2013 Term Loan

2013 Term Loan

2013 Term Loan

2013 Term Loan

2013 Term Loan

2013 Term Loan

2013 Line of Credit

2013 Line of Credit

2013 Line of Credit

2014 Term Loan

2014 Term Loan

2014 Term Loan

Silicon Valley Bank (SVB)

Alimera Sciences, Inc.(Company)

Alimera Sciences, Inc.(Company)

Alimera Sciences Limited (Limited)

Maximum

Alimera Sciences Limited (Limited)

Alimera Sciences Limited (Limited)

Prime Rate

Alimera Sciences, Inc.(Company)

Alimera Sciences Limited (Limited)

Minimum

Silicon Valley Bank (SVB)

Silicon Valley Bank (SVB)

Silicon Valley Bank (SVB)

Alimera Sciences Limited (Limited)

Silicon Valley Bank (SVB)

Silicon Valley Bank (SVB)

Alimera Sciences Limited (Limited)

Hercules Technology Growth Capital, Inc.

Hercules Technology Growth Capital, Inc.

Alimera Sciences Limited (Limited)

Installment

Silicon Valley Bank (SVB)

Silicon Valley Bank (SVB)

Hercules Technology Growth Capital, Inc.

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term loan amount

'

'

'

'

'

'

'

'

'

$5,000,000

'

'

'

'

'

$10,000,000

'

Company entitled to borrow

'

'

'

'

'

'

'

'

'

'

'

'

15,000,000

'

'

'

'

Loss from early extinguishment of debt

440,000

153,000

440,000

153,000

'

153,000

153,000

'

'

'

'

'

'

'

'

'

'

Interest-only payment period

'

'

'

'

'

'

'

'

'

'6 months

'

'

'

'

'

'18 months

'

Frequency of periodic payment monthly installments

'

'

'

'

'

'

'

'

'

36

'

'

'

'

'

'

'

Interest rate on term loan

'

'

'

'

'

'

'

'

'

7.50%

'

'

'

'

'

'

10.90%

Eligible accounts receivable percentage used to determine advances against line of credit

'

'

'

'

'

'

'

'

'

'

'

'

80.00%

'

'

'

'

Basis spread on variable rate

'

'

'

'

'

'

'

'

'

'

'

'

'

2.75%

'

7.65%

'

Unused capacity commitment fee percentage

'

'

'

'

'

'

'

'

'

'

'

'

0.25%

'

'

'

'

An upfront fee payment to Lenders

'

'

'

'

'

'

'

'

'

25,000

'

'

'

'

'

262,500

'

Number of shares called by warrants

'

'

'

'

31,818

'

'

'

'

'

'

'

'

'

285,016

'

'

Exercise price on warrants (in dollars per share)

'

'

'

'

$2.86

'

'

'

'

'

'

'

'

'

$6.14

'

'

Number of shares called by warrants, remaining period

'

'

'

'

'7 years 4 months 24 days

'

'

'

'

'

'

'

'

'

'

'

'

Estimated incremental fair value received by the holder upon re-pricing of warrants

'

'

'

'

46,000

'

'

'

'

'

'

'

'

'

'

'

'

Interest Expense, Debt

'

'

'

'

'

'

'

11,000

44,000

'

'

'

'

'

'

'

'

Commitment fee payment

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

Deferred financing costs capitalized

'

'

'

'

'

'

'

'

'

'

'

'

49,000

'

'

'

'

Prepayment fee

'

'

'

'

'

'

'

'

'

'

133,000

'

'

'

'

'

'

Prepayment fee percentage within the first year of borrowing

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.25%

'

Termination fee amount

'

'

'

'

'

'

'

'

'

'

'

113,000

'

'

'

'

'

Increase of term loan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000,000

25,000,000

'

Interest only payment period, extension period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'18 months

'

Debt issuance costs incurred

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$383,000

'

Warrants exercisable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

60.00%

'

'

Warrants that will become exercisable upon obtaining additional financing amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

40.00%

'

'

Earnings_Loss_Per_Share_EPS_An

Earnings (Loss) Per Share (EPS) - AntiDilutive Securities Excluded (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share (in shares)	20,630,686	25,597,277	25,141,965	25,597,277
Series A convertible preferred stock	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share (in shares)	12,781,954	15,037,593	12,781,954	15,037,593
Series A convertible preferred stock warrants	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share (in shares)	0	4,511,279	4,511,279	4,511,279
Common stock warrants	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share (in shares)	248,964	152,567	248,964	152,567
Stock options	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share (in shares)	7,599,768	5,895,838	7,599,768	5,895,838

Earnings_Loss_Per_Share_EPS_Ba

Earnings (Loss) Per Share (EPS) - Basic and Diluted EPS (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Earnings Per Share [Abstract]	'	'	'	'
Numerator for basic EPS - net income (loss) applicable to common stockholders	$1,116,000	($21,313,000)	($19,643,000)	($35,297,000)
Change in fair value of derivative warrant liability	-8,054,000	0	0	0
Numerator for diluted EPS - net loss applicable to common stockholders after assumed conversions	($6,938,000)	($21,313,000)	($19,643,000)	($35,297,000)
Denominator for basic EPS - weighted average shares outstanding (shares)	40,275,638	31,574,858	38,076,968	31,560,294
Preferred stock warrants (shares)	2,272,616	0	0	0
Denominator for diluted EPS - adjusted weighted average shares and assumed conversions outstanding (shares)	42,548,254	31,574,858	38,076,968	31,560,294
Basic EPS (in dollars per share)	$0.03	($0.67)	($0.52)	($1.12)
Diluted EPS (in dollars per share)	($0.16)	($0.67)	($0.52)	($1.12)

Preferred_Stock_Detail

Preferred Stock (Detail) (USD $)	3 Months Ended		6 Months Ended			1 Months Ended	0 Months Ended		1 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Apr. 30, 2014	Jun. 30, 2013	Oct. 02, 2012	Apr. 30, 2014
						Common stock	Series A convertible preferred stock	Series A convertible preferred stock	Series A convertible preferred stock
Conversion of Stock [Line Items]	'	'	'	'	'	'	'	'	'
Number of preferred stock and warrants.	'	'	'	'	'	'	'	1,000,000	'
Warrants to purchase additional shares	'	'	'	'	'	'	'	300,000	'
Gross proceeds under securities purchase agreement	'	'	'	'	'	'	'	$40,000,000	'
Estimated total stock issuance cost	'	'	'	'	'	'	'	560,000	'
Conversion rate of Series A Convertible Preferred Stock issued upon exercise of warrants into common stock (in dollar per share)	'	'	'	'	'	'	'	$40	'
Initial conversion price (in dollars per share)	'	'	'	'	'	'	'	$2.91	'
Initial conversion price subjected to adjustment (in dollars per share)	'	'	'	'	'	'	'	$3.16	'
Initial conversion price subjected to adjustment two (in dollars per share)	'	'	'	'	'	'	$2.66	$2.66	'
Preferred stock converted to common stock per share (in dollars per share)	'	'	'	'	'	'	'	$10	'
Proceeds from issuance of preferred stock	'	'	'	'	'	'	'	30,000,000	'
Contingent beneficial conversion feature	0	4,950,000	0	4,950,000	'	'	4,950,000	'	'
Proportion of each unit of shares (in shares)	'	'	'	'	'	'	'	0.3	'
Exercise price of warrants (in dollars per share)	'	'	'	'	'	'	'	$44	'
Estimated fair value of derivatives	21,457,000	'	21,457,000	'	16,381,000	'	'	'	'
Gain (loss) on change in fair value of derivatives	$8,054,000	($6,742,000)	($5,076,000)	($12,336,000)	'	'	'	'	'
Common stock issued upon conversion of convertible securities	'	'	'	'	'	2,255,639	'	'	'
Convertible securities converted	'	'	'	'	'	'	'	'	150,000

Common_Stock_Detail

Common Stock (Detail) (USD $)	6 Months Ended		3 Months Ended		6 Months Ended		1 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jan. 31, 2014
			Common stock	Common stock	Common stock	Common stock	Private placement
			Employee Stock	Employee Stock	Employee Stock	Employee Stock	Common stock
Class of Stock [Line Items]	'	'	'	'	'	'	'
Issuance of stock (in shares)	'	'	'	'	'	'	6,250,000
Share purchase price of shares issued (in dollars per share)	'	'	'	'	'	'	$6
Proceeds from sale of common stock	$37,543,000	$33,000	$43,000	$33,000	$43,000	$33,000	$37,500,000
Payment of stock issuance cost	$2,389,000	$0	'	'	'	'	$2,389,000
Shares acquired under plan (shares)	'	'	23,487	15,174	23,487	15,174	'

Stock_Incentive_Plans_Addition

Stock Incentive Plans - Additional Information (Detail) (USD $)	6 Months Ended	12 Months Ended	3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
			Stock options	Stock options	Stock options	Stock options	Employee Stock	Employee Stock	Employee Stock	Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Share-based compensation expense	'	'	$904	$448	$1,829	$976	$12	$7	$20	$13
Weighted average contractual term (years)	'5 years 9 months 13 days	'5 years 5 months 12 days	'	'	'2 years 7 months 18 days	'	'	'	'	'
Share-based compensation not yet recognized	'	'	$5,668	'	$5,668	'	'	'	'	'

Stock_Incentive_Plans_Summary_

Stock Incentive Plans - Summary of Stock Option Transactions (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Options	'	'	'	'	'
Options outstanding at beginning of period (in shares)	7,408,977	5,849,838	7,566,438	5,493,079	'
Grants (in shares)	315,000	172,500	315,000	560,000	'
Forfeitures (in shares)	-99,167	-106,500	-99,167	-122,412	'
Exercises (in shares)	-25,042	-20,000	-182,503	-34,829	'
Options outstanding at year end (in shares)	7,599,768	5,895,838	7,599,768	5,895,838	'
Options exercisable at year end (in shares)	3,903,668	2,836,201	3,903,668	2,836,201	3,304,981
Weighted average per share fair value of options granted during the period (in dollars per share)	$4.50	$4.01	$4.50	$2.38	'
Weighted Average Exercise Price	'	'	'	'	'
Options outstanding at beginning of period (in dollars per share)	$2.76	$2.63	$2.74	$2.67	'
Grants (in dollars per share)	$5.66	$5.26	$5.66	$3.09	'
Forfeitures (in dollars per share)	$2.54	$1.66	$2.54	$2.06	'
Exercises (in dollars per share)	$1.88	$1.33	$1.83	$1.70	'
Options outstanding at year end (in dollars per share)	$2.88	$2.73	$2.88	$2.73	'
Options exercisable at year end (in dollars per share)	$3.15	$3.05	$3.15	$3.05	$3.09

Stock_Incentive_Plans_Addition1

Stock Incentive Plans - Additional Stock Option Transactions (Detail) (USD $)	6 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013	Mar. 31, 2014	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'	'	'	'	'
Outstanding, Shares	7,599,768	7,566,438	7,408,977	5,895,838	5,849,838	5,493,079
Options, Weighted Average Exercise Price (in dollars per share)	$2.88	$2.74	$2.76	$2.73	$2.63	$2.67
Outstanding, Weighted Average Contractual Term (years)	'7 years 4 months 5 days	'7 years 7 months 17 days	'	'	'	'
Outstanding, Aggregate Intrinsic Value	$25,657	$17,759	'	'	'	'
Exercisable, Shares	3,903,668	3,304,981	'	2,836,201	'	'
Exercisable, Weighted Average Exercise Price (in dollars per share)	$3.15	$3.09	'	$3.05	'	'
Exercisable, Weighted Average Contractual Term (years)	'5 years 9 months 13 days	'5 years 5 months 12 days	'	'	'	'
Exercisable, Aggregate Intrinsic Value	12,963	7,589	'	'	'	'
Expected to vest, Shares	2,966,181	3,469,118	'	'	'	'
Expected to vest, Weighted Average Exercise Price (in dollars per share)	$2.63	$2.48	'	'	'	'
Expected to vest, Weighted Average Contractual Term (years)	'8 years 11 months 5 days	'9 years 3 months	'	'	'	'
Expected to vest, Aggregate Intrinsic Value	$10,108	$8,314	'	'	'	'

Income_Taxes_Detail

Income Taxes (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Federal NOL	'
Income Taxes [Line Items]	'
Net operating loss carry-forwards	$82,380
State NOL	'
Income Taxes [Line Items]	'
Net operating loss carry-forwards	$65,840

Fair_Value_Assets_Measured_at_

Fair Value - Assets Measured at Fair Value on Recurring Basis (Detail) (Recurring basis, USD $)	Jun. 30, 2014		Dec. 31, 2013
In Thousands, unless otherwise specified
Assets:	'		'
Cash equivalents	$29,194	[1]	$6,944	[1]
Assets measured at fair value	29,194		6,944
Liabilities:	'		'
Derivative warrant liability	21,457	[2]	16,381	[2]
Liabilities measured at fair value	21,457		16,381
Level 1	'		'
Assets:	'		'
Cash equivalents	29,194	[1]	6,944	[1]
Assets measured at fair value	29,194		6,944
Liabilities:	'		'
Derivative warrant liability	0	[2]	0	[2]
Liabilities measured at fair value	0		0
Level 2	'		'
Assets:	'		'
Cash equivalents	0	[1]	0	[1]
Assets measured at fair value	0		0
Liabilities:	'		'
Derivative warrant liability	21,457	[2]	16,381	[2]
Liabilities measured at fair value	21,457		16,381
Level 3	'		'
Assets:	'		'
Cash equivalents	0	[1]	0	[1]
Assets measured at fair value	0		0
Liabilities:	'		'
Derivative warrant liability	0	[2]	0	[2]
Liabilities measured at fair value	$0		$0
[1]	The carrying amounts approximate fair value due to the short-term maturities of the cash equivalents.
[2]	The Company uses the Black-Scholes option pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments. Assumptions used are generally consistent with those disclosed for stock based compensation (see Note 12).